おすすめの製品
グレード
analytical standard
アッセイ
~95% (HPLC)
~95%
テクニック
HPLC: suitable
gas chromatography (GC): suitable
アプリケーション
food and beverages
フォーマット
neat
保管温度
−20°C
SMILES記法
CC(O)=O.CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c3c(C)cc4c(C(C)C)c(O)c(O)c(C=O)c4c3O
InChI
1S/C30H30O8.C2H4O2/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36;1-2(3)4/h7-12,33-38H,1-6H3;1H3,(H,3,4)
InChI Key
NIOHNDKHQHVLKA-UHFFFAOYSA-N
関連するカテゴリー
アプリケーション
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
生物化学的／生理学的作用
Reported to inhibit the autolytic conversion of pepsinogen to pepsin.
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Acute Tox. 4 Oral - Carc. 2
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
個人用保護具 (PPE)
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
Christian Billard
Molecular cancer research : MCR, 10(6), 673-676 (2012-04-03)
Despite real advances made in chemoimmunotherapy, chronic lymphocytic leukemia (CLL) is still an incurable disease. New therapeutic strategies based on the restoration of the cell death program seemed relevant. Some members of the Bcl-2 family are critical players in the
Neal Ready et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(4), 781-785 (2011-02-04)
AT-101 is an inhibitor of Bcl-2 family proteins including Bcl-2, Bcl-xL, Mcl-1, and Bcl-w. In vivo and in vitro studies have exhibited broad activity of AT-101, including synergy with docetaxel in non-small cell lung cancer tumor models. We conducted a
Inhibition of pepsinogen activation by gossypol.
T D Tanksley et al.
The Journal of biological chemistry, 245(23), 6456-6461 (1970-12-10)
Studies on the nature of the inhibition by gossypol of the transformation of pepsinogen to pepsin.
R C Wong et al.
The Journal of biological chemistry, 247(5), 1625-1631 (1972-03-10)
Rebecca Suk Heist et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 5(10), 1637-1643 (2010-09-03)
AT-101 is an oral, pan Bcl-2 family protein inhibitor that has demonstrated activity in small cell lung cancer (SCLC) models. A phase I/II study was conducted combining AT-101 with topotecan in relapsed and refractory SCLC. An open-labeled multicenter phase I/II
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）